FibroBiologics gets USPTO notice of allowance for topical fibroblast spheroid wound-healing patent application

FibroBiologics, Inc.

FibroBiologics, Inc.

FBLG

0.00
  • FibroBiologics received a USPTO notice of allowance for a U.S. patent application covering topical 3D fibroblast-spheroid therapy for wound healing.
  • The application includes 19 allowed claims for treating wounds using spheroid fibroblasts, alone or with fibroblast-derived materials.
  • Claims cover chronic wounds, including diabetic patients, aligning with lead program CYWC628 in a Phase 1/2 diabetic foot ulcer trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220830PRIMZONEFULLFEED9750170) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.